Antibacterial activities of liposomal linolenic acids against antibiotic-resistant Helicobacter pylori

Molecular Pharmaceutics

Volumn 9, Issue 9, 2012, Pages 2677-2685

  Obonyo, Marygorret ^a   Zhang, Li ^b,c   Thamphiwatana, Soracha ^b,c   Pornpattananangkul, Dissaya ^c,d   Fu, Victoria ^b   Zhang, Liangfang ^b,c,e  

^a UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

^b UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

^c UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

^d UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

^e UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

bacterial infection; free fatty acid; Helicobacter pylori; linolenic acid; liposome

Indexed keywords

AMOXICILLIN; ANTIINFECTIVE AGENT; LINOLENIC ACID; LIPOSOME; METRONIDAZOLE;

ANTIBACTERIAL ACTIVITY; ANTIBIOTIC RESISTANCE; ARTICLE; BACTERIAL MEMBRANE; BACTERIAL STRAIN; BACTERIUM ISOLATION; CONTROLLED STUDY; DRUG EFFICACY; HELICOBACTER INFECTION; HELICOBACTER PYLORI; NONHUMAN; PRIORITY JOURNAL;

ANTI-BACTERIAL AGENTS; DRUG RESISTANCE, MICROBIAL; HELICOBACTER INFECTIONS; HELICOBACTER PYLORI; LINOLENIC ACIDS; LIPOSOMES; METRONIDAZOLE;

EID: 84865975043     PISSN: 15438384     EISSN: 15438392     Source Type: Journal    
DOI: 10.1021/mp300243w     Document Type: Article

References (39)

1. Hatakeyama, M.; Brzozowski, T. Pathogenesis of Helicobacter pylori infection Helicobacter 2006, 11, 14-20
2. Gonzalez, C. A.; Agudo, A. Carcinogenesis, prevention and early detection of gastric cancer: Where we are and where we should go Int. J. Cancer 2012, 130, 745-753
3. Gisbert, J. P.; Pajares, J. M. Treatment of Helicobacter pylori infection: The past and the future Eur. J. Intern. Med. 2010, 21, 357-359
4. Paoluzi, O. A.; Visconti, E.; Andrei, F.; Tosti, C.; Lionetti, R.; Grasso, E.; Ranaldi, R.; Stroppa, I.; Pallone, F. Ten and eight-day sequential therapy in comparison to standard triple therapy for eradicating Helicobacter pylori infection: A randomized controlled study on efficacy and tolerability J. Clin. Gastroenterol. 2010, 44, 261-266
5. Yamaoka, Y.; Graham, D. Y.; Lu, H. Should triple therapy for Helicobacter pylori infection be abandoned as no longer effective? US Gastroenterol. Hepatol. Rev. 2008, 4, 65-67
6. Megraud, F. H. pylori antibiotic resistance: Prevalence, importance, and advances in testing Gut 2004, 53, 1374-1384
7. Njume, C.; Afolayan, A. J.; Ndip, R. N. An overview of antimicrobial resistance and the future of medicinal plants in the treatment of Helicobacter pylori infections Afr. J. Pharm. Pharmacol. 2009, 3, 685-699
8. O'Connor, A.; Gisbert, J. P.; McNamara, D.; O'Morain, C. Treatment of Helicobacter pylori Infection 2011 Helicobacter 2011, 16, 53-58
9. Desbois, A. P.; Smith, V. J. Antibacterial free fatty acids: Activities, mechanisms of action and biotechnological potential Appl. Microbiol. Biotechnol. 2010, 85, 1629-1642
10. Petschow, B. W.; Batema, R. P.; Ford, L. L. Susceptibility of Helicobacter pylori to bactericidal properties of medium-chain monoglycerides and free fatty acids Antimicrob. Agents Chemother. 1996, 40, 302-306 (Pubitemid 26049339)
11. Prajapati, H. N.; Dalrymple, D. M.; Serajuddin, A. T. M. A comparative evaluation of mono-, di- and triglyceride of medium chain fatty acids by lipid/surfactant/water phase diagram, solubility determination and dispersion testing for application in pharmaceutical dosage form development Pharm. Res. 2012, 29, 285-305
12. Yang, D.; Pornpattananangkul, D.; Nakatsuji, T.; Chan, M.; Carson, D.; Huang, C. M.; Zhang, L. The antimicrobial activity of liposomal lauric acids against Propionibacterium acnes Biomaterials 2009, 30, 6035-6040
13. Huang, C. M.; Chen, C. H.; Pornpattananangkul, D.; Zhang, L.; Chan, M.; Hsieh, M. F. Eradication of drug resistant Staphylococcus aureus by liposomal oleic acids Biomaterials 2011, 32, 214-221
14. Huh, A. J.; Kwon, Y. J. Nanoantibiotics: A new paradigm for treating infectious diseases using nanomaterials in the antibiotics resistant era J. Controlled Release 2011, 156, 128-145
15. Bhardwaj, V.; Hariharan, S.; Bala, I.; Lamprecht, A.; Kumar, N.; Panchagnula, R.; Kumar, M. N. V. R. Pharmaceutical aspects of polymeric nanoparticles for oral drug delivery J. Biomed. Nanotechnol. 2005, 1, 235-258
16. Roger, E.; Lagarce, F.; Garcion, E.; Benoit, J.-P. Biopharmaceutical parameters to consider in order to alter the fate of nanocarriers after oral delivery Nanomedicine 2010, 5, 287-306
17. Lee, A.; O'Rourke, J.; De Ungria, M. C.; Robertson, B.; Daskalopoulos, G.; Dixon, M. F. A standardized mouse model of Helicobacter pylori infection: Introducing the Sydney strain Gastroenterology 1997, 112, 1386-1397 (Pubitemid 27157555)
18. Obonyo, M.; Sabet, M.; Cole, S. P.; Ebmeyer, J.; Uematsu, S.; Akira, S.; Guiney, D. G. Deficiencies of myeloid differentiation factor 88, toll-like receptor 2 (TLR2), or TLR4 produce specific defects in macrophage cytokine secretion induced by Helicobacter pylori Infect. Immun. 2007, 75, 2408-2414 (Pubitemid 46744331)
19. Jeong, J. Y.; Berg, D. E. Mouse-colonizing Helicobacter pylori SS1 is unusually susceptible to metronidazole due to two complementary reductase activities Antimicrob. Agents Chemother. 2000, 44, 3127-3132
20. Tsugawa, H.; Suzuki, H.; Nakagawa, I.; Nishizawa, T.; Saito, Y.; Suematsu, M.; Hibi, T. Alpha-ketoglutarate oxidoreductase, an essential salvage enzyme of energy metabolism, in coccoid form of Helicobacter pylori Biochem. Biophys. Res. Commun. 2008, 376, 46-51
21. Al-Nasiry, S.; Geusens, N.; Hanssens, M.; Luyten, C.; Pijnenborg, R. The use of Alamar Blue assay for quantitative analysis of viability, migration and invasion of choriocarcinoma cells Hum. Reprod. 2007, 22, 1304-1309 (Pubitemid 47062799)
22. Thompson, L. J.; Danon, S. J.; Wilson, J. E.; O'Rourke, J. L.; Salama, N. R.; Falkow, S.; Mitchell, H.; Lee, A. Chronic Helicobacter pylori infection with Syndey Strain 1 and a newly identified mouse-adapted strain (Sydney Strain 2000) in C57BL/6 and BALB/c mice Infect. Immun. 2004, 72, 4668-4679 (Pubitemid 38989327)
23. Ha, T. Single-molecule fluorescence resonance energy transfer Methods 2001, 25, 78-86 (Pubitemid 32905290)
24. Bagalkot, V.; Zhang, L.; Levy-Nissenbaum, E.; Jon, S.; Kantoff, P. W.; Langer, R.; Farokhzad, O. C. Quantum dot-aptamer conjugates for synchronous cancer imaging, therapy, and sensing of drug delivery based on bi-fluorescence resonance energy transfer Nano Lett. 2007, 7, 3065-3070 (Pubitemid 350132931)
25. Kusters, J. G.; van Vliet, A. H.; Kuipers, E. J. Pathogenesis of Helicobacter pylori infection Clin. Microbiol. Rev. 2006, 19, 449-490 (Pubitemid 44134306)
26. Andersen, L. P.; Rasmussen, L. Helicobacter pylori -Coccoid forms and biofilm formation FEMS Immunol. Med. Microbiol. 2009, 56, 112-115
27. She, F. F.; Su, D. H.; Lin, J. Y.; Zhou, L. Y. Virulence and potential pathogenicity of coccoid Helicobacter pylori induced by antibiotics World J. Gastroenterol. 2001, 7, 254-258 (Pubitemid 32377480)
28. Megraud, F.; Trimoulet, P.; Lamouliatte, H.; Boyanova, L. Bactericidal effect of amoxicillin on Helicobacter pylori in an in vitro model using epithelial cells Antimicrob. Agents Chemother. 1991, 35, 869-872
29. Canton, R.; de Argila, C. M.; de Rafael, L.; Baquero, F. Antimicrobial resistance in Helicobacter pylori Rev. Med. Microbiol. 2001, 12, 47-61 (Pubitemid 32095755)
30. Co, E.-M. A.; Schiller, N. L. Resistance mechanisms in an in vitro-selected amoxicillin-resistant strain of Helicobacter pylori Antimicrob. Agents Chemother. 2006, 50, 4174-4176 (Pubitemid 44865163)
31. Van Zwet, A. A.; Thijs, J. C.; de Graaf, B. Explanations for high rates of eradication with triple therapy using metronidazole in patients harboring metronidazole-resistant Helicobacter pylori strains Antimicrob. Agents Chemother. 1995, 39, 250-252
32. Weel, J. F.; van der Hulst, R. W.; Gerrits, Y.; Tytgat, G. N.; van der Ende, A.; Dankert, J. Heterogeneity in susceptibility to metronidazole among Helicobacter pylori isolates from patients with gastritis or peptic ulcer disease J. Clin. Microbiol. 1996, 34, 2158-2162 (Pubitemid 26272196)
33. Sun, C. Q.; O'Connor, C. J.; Roberton, A. M. Antibacterial actions of fatty acids and monoglycerides against Helicobacter pylori FEMS Immunol. Med. Microbiol. 2003, 36, 9-17 (Pubitemid 36515078)
34. Knapp, H. R.; Melly, M. A. Bactericidal effects of polyunsaturated fatty acids J. Infect. Dis. 1986, 154, 84-94 (Pubitemid 16088306)
35. Lai, S. K.; Wang, Y.-Y.; Hanes, J. Mucus-penetrating nanoparticles for drug and gene delivery to mucosal tissues Adv. Drug Delivery Rev. 2009, 61, 158-171
36. Gao, W.; Chan, J. M.; Farokhzad, O. C. pH-responsive nanoparticles for drug delivery Mol. Pharmaceutics 2010, 7, 1913-1920
37. Yang, M.; Lai, S. K.; Wang, Y. Y.; Zhong, W. X.; Happe, C.; Zhang, M.; Fu, J.; Hanes, J. Biodegradable nanoparticles composed entirely of safe materials that rapidly penetrate human mucus Angew. Chem., Int. Ed. 2011, 50, 2597-2600
38. Lai, S. K.; Wang, Y. Y.; Hida, K.; Cone, R.; Hanes, J. Nanoparticles reveal that human cervicovaginal mucus is riddled with pores larger than viruses Proc. Natl. Acad. Sci. U.S.A. 2010, 107, 598-603
39. Tang, B. C.; Dawson, M.; Lai, S. K.; Wang, Y. Y.; Suk, J. S.; Yang, M.; Zeitlin, P.; Boyle, M. P.; Fu, J.; Hanes, J. Biodegradable polymer nanoparticles that rapidly penetrate the human mucus barrier Proc. Natl. Acad. Sci. U.S.A. 2009, 106, 19268-19273